Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1223-1233

  Kim, Soon Sun ^a   Hwang, Jae Chul ^a   Lim, Sun Gyo ^a   Ahn, Seon Joo ^a   Cheong, Jae Youn ^a   Cho, Sung Won ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905593851     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.145     Document Type: Article

References (30)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337 : 1733-45.
2. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 : 65-73.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 : 167-85.
4. Sung JJ, Tsoi KK, Wong VW et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28 : 1067-77.
5. Singal AK, Salameh H, Kuo YF et al. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38 : 98-106.
6. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 : 886-93.
7. Zoutendijk R, Reijnders JG, Zoulim F et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62 : 760-5.
8. Papatheodoridis GV, Manolakopoulos S, Touloumi G et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60 : 1109-16.
9. Koo JH, Lee MH, Kim SS et al. Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy. Clin Biochem 2012; 45 : 31-6.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 : 1020-2.
11. Wong VW, Chan SL, Mo F et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28 : 1660-5.
12. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50 : 80-8.
13. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 : S35-50.
14. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefi ts of antiviral therapy. J Hepatol 2012; 57 : 442-50.
15. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year openlabel follow-up study. Lancet 2013; 381 : 468-75.
16. Wong GL, Chan HL, Mak CH et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58 : 1537-47.
17. Hosaka T, Suzuki F, Kobayashi M et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58 : 98-107.
18. Papatheodoridis GV, Lampertico P, Manolakopoulos S et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53 : 348-56.
19. Eun JR, Lee HJ, Kim TN et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53 : 118-25.
20. Yang SC, Lee CM, Hu TH et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother 2013; 68 : 2154-63.
21. Shafritz DA, Shouval D, Sherman HI et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305 : 1067-73.
22. Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas defi ne distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120 : 1763-73.
23. Lok AS, Hadziyannis SJ, Weller IV et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25 : 1283-7.
24. Fong TL, Di Bisceglie AM, Gerber MA et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18 : 1313-8.
25. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 : 335-52.
26. Chang TT, Lin HC, Lee SD et al. Clinical signifi cance of serum type-III procollagen aminopropeptide in hepatitis B virus-related liver diseases. Scand J Gastroenterol 1989; 24 : 533-8.
27. Trinchet JC, Hartmann DJ, Pateron D et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol 1991; 12 : 139-44.
28. Ramadori G, Zohrens G, Manns M et al. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 1991; 21 : 323-30.
29. Jung KS, Kim SU, Ahn SH et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53 : 885-94.
30. Sarin SK, Kumar M. Predictive scores for hepatocellular carcinoma development in chronic hepatitis B virus infection: " does one size fi t all? " Gastroenterology 2012; 142 : 1038-40.